Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 736 participants.

Also called NCT02058160

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 736 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02058160
  • EudraCT 2013-003132-79
Other papers using this trial's data
  • Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial Diabetes, obesity & metabolism, 2017-10 DOI, PubMed 28386990, PMC5638095 In the PMC Open Access subset under CC BY-NC.
  • Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial Diabetes care, 2016-11 DOI, PubMed 27650977 PubMed links an erratum for this paper. Erratum: PMID 28428368

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Chile, Czechia, Denmark, Estonia, Hungary, Lithuania, Mexico, Netherlands, Poland, Romania, Russia, Slovakia, Spain, Sweden, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02058160. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-07 (actual). Results posted on 2017-02-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Acronym
LixiLan-L
Intervention (Drug)
Insulin glargine/lixisenatide (HOE901/AVE0010)
Intervention (Drug)
Insulin glargine (HOE901)
Intervention (Drug)
Metformin (Background Drug)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02058160
Content hash
acb0e452c9d8168e6b15e5f5707781f85c560c44c633b386dc25d90849f1e087